VY
VYGR.O
—
NASDAQ
Biotechnology
Vygr.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-326,6 %
ROE
-61,1 %
Net margin
-296,5 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$3,13
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Voyager Therapeutics operates as a biotechnology company developing therapies for rare diseases, generating revenue through licensing and collaboration agreements with partners such as Novartis and Alexion.
Business. Voyager Therapeutics operates as a biotechnology company developing therapies for rare diseases, generating revenue through licensing and collaboration agreements with partners such as Novartis and Alexion.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability→
-61,1 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to VYGR.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Voyager Therapeutics operates as a biotechnology company developing therapies for rare diseases, generating revenue through licensing and collaboration agreements with partners such as Novartis and Alexion.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATEDVoyager Therapeutics maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet holds $65.3 million in cash and equivalents against total liabilities of $56.2 million, providing a current liquidity buffer. However, the company faces significant cash burn, with operating cash flow at -$132.5 million and capital expenditures of $2.6 million, indicating heavy reliance on existing cash reserves or future financing to sustain operations.
Profitability metrics reflect the pre-commercial stage of the business, with a net loss of $119.7 million and an operating loss of $131.8 million. Return on equity stands at -61.1% and return on assets at -47.5%, consistent with early-stage biotechnology firms investing heavily in research and development before achieving commercial scale. These negative returns are expected given the lack of significant product revenue relative to operational costs.
Key takeaways
- Zero debt structure provides financial flexibility but does not offset high cash burn.
- Operating cash flow of -$132.5 million significantly exceeds cash reserves of $65.3 million.
- Revenue of $40.4 million is insufficient to cover operating losses of $131.8 million.
- Strategic partnerships with Novartis and Alexion are key to pipeline advancement.
- Low dilution and liquidity risk flags suggest no immediate distress signals in filings.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$3,01
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$196.1M
Net cashⓘ
$65.3M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-47.5%
ROEⓘ
-61.1%
Cash conversionⓘ
111.0%
CapEx / revenueⓘ
6.4%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships3 disclosed relationships · 2 types · extracted from filings & disclosures
Partners2
Neurocrine Biosciences IncNBIX.OPartner95%Source ↗
NOVARTIS AGNVS.OPartner95%Source ↗
Subsidiaries1
EX21:3cea8cef6cb1EX21:3cea8cef6cb1Subsidiarie97%
Supply chain
Vendors → VYGR ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution11 analysts
Strong buy6
Buy5
Hold0
Sell0
Strong sell0
12-month price target$14,89 · Median $12,00
Low $8,00High $25,00
Operating income · consensus-110,6M USD
EPS surprise
−24,3 %
reported vs consensus · miss
Revenue surprise
−2,0 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$8,00
Mean$14,89
Median$12,00
High$25,00
Spot$3,01
+394.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-326,6 %Below median
Net Margin-296,5 %Below median
ROE-61,1 %Below median
Capex / Rev6,4 %Above P75
D/E0,00Above median
Cash Conv1,11Above P75
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 844 000 sh12 grants12 insiders
- Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $3,43grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $3,43grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $3,43grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $3,43grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $3,43grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $3,43grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $3,43grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $3,43grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $3,43grant · 2026-06-09
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 210 000 @ $3,68grant · 2026-02-06
- COO & CBO · Stock Option (Right to Buy) → Common StockAcquired 210 000 @ $3,68grant · 2026-02-06
- Chief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 154 000 @ $3,68grant · 2026-02-06
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- Voyager Therapeutics, Inc. Market data — financials · 2026-08-02
- reconciler_enqueue (reconciler) on VYGR.O · 2026-08-02
- VYGR.O HA canonical relationships · 2026-08-02
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$42M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$13M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Alfred W. SandrockPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 11 sellsnet -$298K6 insiders · last 365d
- Director, President and CEO · Common StockSold 11 511 @ $3,87$45K · 2026-04-02
- SVP and General Counsel · Common StockOther 50 000 · 2026-04-01
- COO & CBO · Common StockSold 6 458 @ $3,77$24K · 2026-02-24
- Chief Scientific Officer · Common StockSold 4 174 @ $3,76$16K · 2026-02-24
- Chief Financial Officer · Common StockSold 4 668 @ $3,77$18K · 2026-02-24
- Director, President and CEO · Common StockSold 14 197 @ $3,79$54K · 2026-02-24
- COO & CBO · Common StockSold 3 882 @ $3,44$13K · 2026-02-18
- Director, President and CEO · Common StockSold 11 732 @ $3,41$40K · 2026-02-18
- Chief Scientific Officer · Common StockSold 3 301 @ $3,44$11K · 2026-02-18
- Chief Scientific Officer · Common StockSold 3 525 @ $3,85$14K · 2026-02-10
- Director, President and CEO · Common StockSold 12 192 @ $3,78$46K · 2026-02-10
- COO & CBO · Common StockSold 4 569 @ $3,85$18K · 2026-02-10
- Chief Scientific Officer · Common StockOther 33 000 · 2026-02-06
- Chief Medical Officer · Common StockOther 45 000 · 2026-02-06
- COO & CBO · Common StockOther 45 000 · 2026-02-06
Short positioning
3.8Mshares short+7.3% vs prior
4.57days to cover
71.3%short of daily vol
2fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
VYGR.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data— missing data
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-09 00:00 UTCINSIDER9 insider transactions — 2026-06 9 derivative
2026-06-09 00:00 UTCINSIDER9 insider transactions — 2026-06 9 derivative
2026-06-09INSIDERMACKEY CATHERINE J acquired 30.0k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERHyman Steven acquired 30.0k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERVitale Nancy acquired 30.0k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDEROnyia Jude acquired 30.0k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERGERAGHTY JAMES A acquired 30.0k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERHiggins Michael J acquired 30.0k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERSCANGOS GEORGE A acquired 30.0k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERColon Grace acquired 30.0k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERPIERCE GLENN acquired 30.0k sh Stock Option (Right to Buy) — Director
2026-04-02 00:00 UTCINSIDER2 insider transactions — 2026-04
2026-04-02 00:00 UTCINSIDER2 insider transactions — 2026-04
2026-04-02INSIDERSandrock Alfred sold 11.5k sh — Director, President and CEO ~$45k
2026-04-01INSIDERShiferman Gregory L. transacted 50.0k sh — SVP and General Counsel
2026-02-24 00:00 UTCINSIDER16 insider transactions — 2026-02 · net sell $253k 3 derivative
2026-02-24 00:00 UTCINSIDER16 insider transactions — 2026-02 · net sell $253k 3 derivative
2026-02-24INSIDERSwartz Robin sold 6.5k sh — COO & CBO ~$24k
2026-02-24INSIDERCarter Todd Alfred sold 4.2k sh — Chief Scientific Officer ~$16k
2026-02-24INSIDERJorgensen Nathan D. sold 4.7k sh — Chief Financial Officer ~$18k
2026-02-24INSIDERSandrock Alfred sold 14.2k sh — Director, President and CEO ~$54k
2026-02-18INSIDERSwartz Robin sold 3.9k sh — COO & CBO ~$13k
2026-02-18INSIDERSandrock Alfred sold 11.7k sh — Director, President and CEO ~$40k
2026-02-18INSIDERCarter Todd Alfred sold 3.3k sh — Chief Scientific Officer ~$11k
2026-02-10INSIDERCarter Todd Alfred sold 3.5k sh — Chief Scientific Officer ~$14k
2026-02-10INSIDERSandrock Alfred sold 12.2k sh — Director, President and CEO ~$46k
2026-02-10INSIDERSwartz Robin sold 4.6k sh — COO & CBO ~$18k
2026-02-06INSIDERCarter Todd Alfred transacted 33.0k sh — Chief Scientific Officer
2026-02-06INSIDERFerguson Toby transacted 45.0k sh — Chief Medical Officer
2026-02-06INSIDERSwartz Robin transacted 45.0k sh — COO & CBO
Showing the 40 most recent of 46 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage